[{"id":"d92c9e11-bf8f-4526-95a3-ebcab2c24614","acronym":"","url":"https://clinicaltrials.gov/study/NCT05317078","created_at":"2022-04-07T12:57:14.157Z","updated_at":"2024-07-02T16:35:23.817Z","phase":"Phase 1","brief_title":"A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications","source_id_and_acronym":"NCT05317078","lead_sponsor":"Amgen","biomarkers":" CLDN6","pipe":" | ","alterations":" CLDN6 expression","tags":["CLDN6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AMG 794"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 02/28/2023","start_date":" 02/28/2023","primary_txt":" Primary completion: 08/10/2026","primary_completion_date":" 08/10/2026","study_txt":" Completion: 02/23/2028","study_completion_date":" 02/23/2028","last_update_posted":"2024-01-11"}]